Boston Scientific has signed a definitive agreement for the acquisition of an Ajax Health company, Cortex, to bolster its cardiac ablation portfolio. The companies did not disclose the financial terms of the deal.

Cortex adds to Boston Scientific’s electrophysiology portfolio amid treatment shifts in the space driven by new pulsed field ablation devices.

As Boston Scientific’s pulsed field ablation business continues to grow, the medtech aims to nourish the program with the acquisition of an atrial fibrillation-focused startup. | Cortex’s FDA-cleared OptiMap system includes a basket-shaped catheter designed to fill the heart’s chambers with 64 electrodes.

Boston Scientific (NYSE:BSX) has agreed to acquire privately held medical technology company, Cortex, Inc. Financial terms of the deal were not disclosed. The transaction is expected to close in the first half of 2025 and have an immaterial impact on adjusted earnings per share in 2025 and be slightly dilutive on a GAAP basis due to amortization expense and acquisition-related net charges.